重大事件
即時報告
8-K
2026-07-23
KALA BIO 提交8-K 配合證券發售 附法律意見書
AI 繁中摘要
申報類型：8-K（最新報告）
事件日期：2026年7月22日
KALA BIO, Inc. 於當日向美國證交會提交了一份招股說明書補充文件（Prospectus Supplement），該文件根據其早前已生效的S-3表格註冊聲明（檔案編號333-295667）及Rule 424(b)規則作出申報，目的是配合公司擬進行的證券發售。
為配合是次發行，公司同時提供了Haynes and Boone, LLP律師事務所出具的法律意見書（作為附件5.1），確認所發行證券的合法性。該意見書已連同相關同意書一併存檔。
是次8-K申報本身不涉及任何財務業績公佈或重大營運變動，但反映公司正積極推進資本市場集資活動。投資者應留意公司後續公佈的發行細節（如規模、定價及資金用途），相關招股書補充文件將提供更詳盡資訊。
展開英文正文
false 0001479419 0001479419 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2026 KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38150 27-0604595 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share KALA The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01.Other Events. On July 22, 2026, the Company filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the offering of securities pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-295667). The Company is filing this report to provide the legal opinion as to the validity of the securities being offered pursuant to the prospectus supplement. Such opinion is attached hereto as Exhibit 5.1. Item 9.01.Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 5.1 Opinion of Haynes and Boone, LLP 23.1 Consent of Haynes and Boone, LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: July 22, 2026 By: /s/ Avi Minkowitz Avi Minkowitz Chief Executive Officer 2